Godsey & Gibb Inc. Acquires 949 Shares of Novartis AG (NYSE:NVS)

Godsey & Gibb Inc. grew its holdings in Novartis AG (NYSE:NVS) by 0.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 192,287 shares of the company’s stock after acquiring an additional 949 shares during the period. Novartis accounts for approximately 1.9% of Godsey & Gibb Inc.’s holdings, making the stock its 29th largest position. Godsey & Gibb Inc.’s holdings in Novartis were worth $18,711,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Financial & Tax Architects LLC raised its holdings in Novartis by 32.8% during the second quarter. Financial & Tax Architects LLC now owns 4,703 shares of the company’s stock valued at $501,000 after buying an additional 1,161 shares in the last quarter. Wealth Alliance boosted its position in Novartis by 5.5% during the second quarter. Wealth Alliance now owns 3,683 shares of the company’s stock worth $392,000 after purchasing an additional 191 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in Novartis by 3.6% during the second quarter. Mercer Global Advisors Inc. ADV now owns 153,055 shares of the company’s stock valued at $16,294,000 after purchasing an additional 5,285 shares during the last quarter. Argent Trust Co grew its stake in Novartis by 4.6% in the 2nd quarter. Argent Trust Co now owns 35,575 shares of the company’s stock valued at $3,787,000 after buying an additional 1,574 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Novartis by 19.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 69,774 shares of the company’s stock worth $7,324,000 after acquiring an additional 11,355 shares during the period. Institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on NVS shares. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank restated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, BMO Capital Markets upped their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have given a hold rating to the stock. According to data from MarketBeat, Novartis has an average rating of “Hold” and a consensus target price of $121.50.

Novartis Trading Down 0.3 %

Shares of NVS stock opened at $99.05 on Thursday. The firm has a fifty day moving average of $101.13 and a 200-day moving average of $109.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The stock has a market cap of $202.46 billion, a price-to-earnings ratio of 11.50, a P/E/G ratio of 1.36 and a beta of 0.57. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The company had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period last year, the business earned $1.74 earnings per share. On average, equities research analysts forecast that Novartis AG will post 7.63 earnings per share for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.